SNIPR001
Prevention of E. coli bloodstream infections in hematological cancer patients
Phase 2Active
Key Facts
Indication
Prevention of E. coli bloodstream infections in hematological cancer patients
Phase
Phase 2
Status
Active
Company
About SNIPR BIOME
SNIPR Biome is a private, clinical-stage biotech developing a novel platform of CRISPR-powered antimicrobials to address the global antimicrobial resistance (AMR) crisis. The company's technology combines bacteriophages or engineered probiotics with CRISPR-Cas systems to selectively kill antibiotic-resistant bacteria while sparing the beneficial microbiome. With a pipeline of five programs, including a candidate in Phase 2, and backing from major foundations and investors, SNIPR is advancing a new class of precision medicines from its Copenhagen headquarters.
View full company profile